"10.1371_journal.pone.0140232","plos one","2015-10-14T00:00:00Z","Sophia K Smith; Wendy Selig; Matthew Harker; Jamie N Roberts; Sharon Hesterlee; David Leventhal; Richard Klein; Bray Patrick-Lake; Amy P Abernethy","School of Nursing, Duke University, Durham, NC, United States of America; WS Collaborative, McLean, VA, United States of America; Clinical Trials Transformation Initiative, Duke Clinical Research Institute, Durham, NC, United States of America; Parent Project Muscular Dystrophy, Hackensack, NJ, United States of America; Pfizer Worldwide Research and Development, Groton, CT, United States of America; U.S. Food and Drug Administration, Silver Spring, MD, United States of America; Flatiron Health, New York, NY, United States of America","Conceived and designed the experiments: SS WS MH JR SH DL RK BP AA. Analyzed the data: SS WS MH JR SH DL RK BP AA. Wrote the paper: SS WS MH JR SH DL RK BP AA.","Financial activities outside the submitted work include (1) Until 3/31/2015, WS was president and CEO of Melanoma Research Alliance and is presently founder and CEO of WS Collaborative LLC; (2) SH serves on the Board of Directors of the Health Research Alliance, a professional organization representing over 60 nonprofit patient organizations and health funding foundations, and has received funding to attend conferences conducted by Parent Project Muscular Dystrophy (PPMD) from PTC Therapeutics, Sarepta Therapeutics, Pfizer, Lilly, Shire, Prosensa, Catabasis, Tivorsan, Summit PLC, and Halo Therapeutics; (3) DL is the director of clinical innovation at Pfizer Worldwide Research and Development, (4) APA is chief medical officer and senior vice president of oncology at Flatiron Health Inc. This does not alter the authors adherence to PLOS ONE policies on sharing data and materials. The other authors have no disclosures related to financial or nonfinancial activities.","2015","10","Sophia K Smith","SKS",9,TRUE,9,NA,9,9,TRUE,TRUE,FALSE,0,NA,FALSE
